NYSE:RCUS - Arcus Biosciences Stock Price, Forecast & News

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Arcus Biosciences Inc (NYSE:RCUS) issued its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.02. The company had revenue of $1.75 million for the quarter, compared to analyst estimates of $1.34 million. Arcus Biosciences had a negative return on equity of 38.73% and a negative net margin of 1,180.37%. View Arcus Biosciences' Earnings History.

Arcus Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Arcus Biosciences.

5 Wall Street analysts have issued 12-month price targets for Arcus Biosciences' shares. Their forecasts range from $15.00 to $22.00. On average, they expect Arcus Biosciences' share price to reach $19.25 in the next twelve months. This suggests a possible upside of 122.5% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.

News coverage about RCUS stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arcus Biosciences earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Arcus Biosciences.

Arcus Biosciences saw a drop in short interest in the month of November. As of November 29th, there was short interest totalling 1,390,000 shares, a drop of 12.0% from the November 14th total of 1,580,000 shares. Based on an average trading volume of 231,500 shares, the short-interest ratio is presently 6.0 days. Currently, 5.5% of the shares of the company are sold short. View Arcus Biosciences' Current Options Chain.

Some companies that are related to Arcus Biosciences include Principia Biopharma (PRNB), Alder Biopharmaceuticals (ALDR), Madrigal Pharmaceuticals (MDGL), Forty Seven (FTSV), Karuna Therapeutics (KRTX), Corcept Therapeutics (CORT), Arvinas (ARVN), Myovant Sciences (MYOV), Nabriva Therapeutics (NBRV), Esperion Therapeutics (ESPR), Innoviva (INVA), Athenex (ATNX), Constellation Pharmaceuticals (CNST), Y-mAbs Therapeutics (YMAB) and Enanta Pharmaceuticals (ENTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics (HZNP), BioDelivery Sciences International (BDSI), Fate Therapeutics (FATE), Galmed Pharmaceuticals (GLMD), Vale (VALE), AcelRx Pharmaceuticals (ACRX), Agile Therapeutics (AGRX), Allena Pharmaceuticals (ALNA), BIOLINERX LTD/S (BLRX) and Cidara Therapeutics (CDTX).

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

Arcus Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (1.35%), Millennium Management LLC (0.41%), Parallel Advisors LLC (0.19%), California State Teachers Retirement System (0.11%), Rhumbline Advisers (0.11%) and Barclays PLC (0.05%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Institutional Ownership Trends for Arcus Biosciences.

RCUS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC and Bailard Inc.. View Insider Buying and Selling for Arcus Biosciences.

RCUS stock was acquired by a variety of institutional investors in the last quarter, including Parallel Advisors LLC, Millennium Management LLC, State Street Corp, California Public Employees Retirement System, Russell Investments Group Ltd., Rhumbline Advisers, Meeder Asset Management Inc. and California State Teachers Retirement System. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Insider Buying and Selling for Arcus Biosciences.

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RCUS stock can currently be purchased for approximately $8.65.

Arcus Biosciences has a market capitalization of $396.69 million and generates $8.35 million in revenue each year. The company earns $-49,590,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.View Additional Information About Arcus Biosciences.

The official website for Arcus Biosciences is http://www.arcusbio.com/.

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]